Key result
Real-world vericiguat is linked to improved functional class, quality of life, and reverse remodeling.
Why the study?
Although the VICTORIA trial showed benefit with vericiguat in heart failure with reduced ejection fraction, understanding how it performs in real-world settings remained essential.
Does vericiguat improve clinical, biochemical, and imaging parameters in patients with heart failure and reduced ejection fraction in real-world settings?
Does vericiguat improve clinical, biochemical, and imaging parameters in patients with heart failure and reduced ejection fraction in real-world settings?
Real-world evidence suggests vericiguat is well-tolerated and effective in improving clinical and echocardiographic outcomes in a broader, older, and more comorbid HFrEF population than studied in the VICTORIA trial.
No takes yet. Share an insight, caveat, or question.
May support vericiguat in real-world worsening HFrEF; extends trial data but remains hypothesis-generating.
Escobar et al. (2025) conducted a review in Heart failure with reduced ejection fraction (n=6,000). Vericiguat was evaluated. Vericiguat use in real-world clinical practice was associated with improvements in quality of life, NYHA functional class, left ventricular reverse remodeling, and low rates of adverse effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: